Advertisement

Wrentham-based wound care company Choice Therapeutics Inc. has sold $582,000 of a planned $3 million equity round, according to a filing with the U.S. Securities and Exchange Commission.

Choice Therapeutics provides medical devices and materials under the TheraBond name for burns, advanced wound care and surgical site infections, using technology designed to protect the wound while wicking excess fluids away from the wound site.

The filing indicates that the funds will be used for general corporate purposes, including $250,000 for the salary of CEO E. James Hutchens, a former executive with Natick medical devices firm Boston Scientific Corp.

SOURCE

Advertisement
Advertisement